Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients

a single institute experience

Jordan Lundberg, Joshua Reardon, Marlo Blazer, Gary Phillips, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Gemcitabine in combination with low-dose cisplatin has shown promising activity in pancreatic cancer with manageable toxicities. The purpose of this study is to assess the activity of a combination of gemcitabine and low-dose cisplatin in the first-line treatment of metastatic and locally advanced pancreatic cancer patients. We conducted a retrospective analysis of all patients diagnosed with metastatic and locally advanced pancreatic cancer who received a combination of gemcitabine and cisplatin in the first-line setting. Patients with baseline cytopenias and elevated liver function tests were included. Patients received cisplatin at 20 mg per square meter followed by gemcitabine at a dose of 1000 mg per square meter at fixed dose rate every 2 weeks. Patients were treated until disease progression or unacceptable toxicities. A total of 58 patients were included in the analysis. The median progression-free survival was 4.4 months [95 % confidence interval (CI) 3.6–6.4], and median overall survival was 6.7 months (95 % CI 4.4–10.9). Thirty-eight patients (66 %) experienced at least one grade 3 or 4 toxicity. The most common grade 3 or 4 toxicity was hematologic toxicity (25 patients, 43 %). Biweekly fixed dose rate gemcitabine combined with low-dose cisplatin shows interesting activity in advanced pancreatic cancer. This regimen is an acceptable alternative for patients ineligible for gemcitabine plus nab-paclitaxel (i.e., those with elevated bilirubin at baseline) or clinical trials. Additionally, this regimen should be considered as a first-line option for those patients with breast cancer susceptibility gene mutations (BRCA1 and/or BRCA2).

Original languageEnglish (US)
Article number4
Pages (from-to)1-6
Number of pages6
JournalMedical Oncology
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Cisplatin
Therapeutics
Confidence Intervals
Neoplasm Genes
Liver Function Tests

Keywords

  • Cisplatin
  • Fixed dose
  • Gemcitabine
  • Pancreatic

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients : a single institute experience. / Lundberg, Jordan; Reardon, Joshua; Blazer, Marlo; Phillips, Gary; Bekaii-Saab, Tanios.

In: Medical Oncology, Vol. 33, No. 1, 4, 01.01.2016, p. 1-6.

Research output: Contribution to journalArticle

@article{c91d26259f0c440e8d8e100e9473e2d6,
title = "Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience",
abstract = "Gemcitabine in combination with low-dose cisplatin has shown promising activity in pancreatic cancer with manageable toxicities. The purpose of this study is to assess the activity of a combination of gemcitabine and low-dose cisplatin in the first-line treatment of metastatic and locally advanced pancreatic cancer patients. We conducted a retrospective analysis of all patients diagnosed with metastatic and locally advanced pancreatic cancer who received a combination of gemcitabine and cisplatin in the first-line setting. Patients with baseline cytopenias and elevated liver function tests were included. Patients received cisplatin at 20 mg per square meter followed by gemcitabine at a dose of 1000 mg per square meter at fixed dose rate every 2 weeks. Patients were treated until disease progression or unacceptable toxicities. A total of 58 patients were included in the analysis. The median progression-free survival was 4.4 months [95 {\%} confidence interval (CI) 3.6–6.4], and median overall survival was 6.7 months (95 {\%} CI 4.4–10.9). Thirty-eight patients (66 {\%}) experienced at least one grade 3 or 4 toxicity. The most common grade 3 or 4 toxicity was hematologic toxicity (25 patients, 43 {\%}). Biweekly fixed dose rate gemcitabine combined with low-dose cisplatin shows interesting activity in advanced pancreatic cancer. This regimen is an acceptable alternative for patients ineligible for gemcitabine plus nab-paclitaxel (i.e., those with elevated bilirubin at baseline) or clinical trials. Additionally, this regimen should be considered as a first-line option for those patients with breast cancer susceptibility gene mutations (BRCA1 and/or BRCA2).",
keywords = "Cisplatin, Fixed dose, Gemcitabine, Pancreatic",
author = "Jordan Lundberg and Joshua Reardon and Marlo Blazer and Gary Phillips and Tanios Bekaii-Saab",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s12032-015-0720-x",
language = "English (US)",
volume = "33",
pages = "1--6",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients

T2 - a single institute experience

AU - Lundberg, Jordan

AU - Reardon, Joshua

AU - Blazer, Marlo

AU - Phillips, Gary

AU - Bekaii-Saab, Tanios

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Gemcitabine in combination with low-dose cisplatin has shown promising activity in pancreatic cancer with manageable toxicities. The purpose of this study is to assess the activity of a combination of gemcitabine and low-dose cisplatin in the first-line treatment of metastatic and locally advanced pancreatic cancer patients. We conducted a retrospective analysis of all patients diagnosed with metastatic and locally advanced pancreatic cancer who received a combination of gemcitabine and cisplatin in the first-line setting. Patients with baseline cytopenias and elevated liver function tests were included. Patients received cisplatin at 20 mg per square meter followed by gemcitabine at a dose of 1000 mg per square meter at fixed dose rate every 2 weeks. Patients were treated until disease progression or unacceptable toxicities. A total of 58 patients were included in the analysis. The median progression-free survival was 4.4 months [95 % confidence interval (CI) 3.6–6.4], and median overall survival was 6.7 months (95 % CI 4.4–10.9). Thirty-eight patients (66 %) experienced at least one grade 3 or 4 toxicity. The most common grade 3 or 4 toxicity was hematologic toxicity (25 patients, 43 %). Biweekly fixed dose rate gemcitabine combined with low-dose cisplatin shows interesting activity in advanced pancreatic cancer. This regimen is an acceptable alternative for patients ineligible for gemcitabine plus nab-paclitaxel (i.e., those with elevated bilirubin at baseline) or clinical trials. Additionally, this regimen should be considered as a first-line option for those patients with breast cancer susceptibility gene mutations (BRCA1 and/or BRCA2).

AB - Gemcitabine in combination with low-dose cisplatin has shown promising activity in pancreatic cancer with manageable toxicities. The purpose of this study is to assess the activity of a combination of gemcitabine and low-dose cisplatin in the first-line treatment of metastatic and locally advanced pancreatic cancer patients. We conducted a retrospective analysis of all patients diagnosed with metastatic and locally advanced pancreatic cancer who received a combination of gemcitabine and cisplatin in the first-line setting. Patients with baseline cytopenias and elevated liver function tests were included. Patients received cisplatin at 20 mg per square meter followed by gemcitabine at a dose of 1000 mg per square meter at fixed dose rate every 2 weeks. Patients were treated until disease progression or unacceptable toxicities. A total of 58 patients were included in the analysis. The median progression-free survival was 4.4 months [95 % confidence interval (CI) 3.6–6.4], and median overall survival was 6.7 months (95 % CI 4.4–10.9). Thirty-eight patients (66 %) experienced at least one grade 3 or 4 toxicity. The most common grade 3 or 4 toxicity was hematologic toxicity (25 patients, 43 %). Biweekly fixed dose rate gemcitabine combined with low-dose cisplatin shows interesting activity in advanced pancreatic cancer. This regimen is an acceptable alternative for patients ineligible for gemcitabine plus nab-paclitaxel (i.e., those with elevated bilirubin at baseline) or clinical trials. Additionally, this regimen should be considered as a first-line option for those patients with breast cancer susceptibility gene mutations (BRCA1 and/or BRCA2).

KW - Cisplatin

KW - Fixed dose

KW - Gemcitabine

KW - Pancreatic

UR - http://www.scopus.com/inward/record.url?scp=84951099597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951099597&partnerID=8YFLogxK

U2 - 10.1007/s12032-015-0720-x

DO - 10.1007/s12032-015-0720-x

M3 - Article

VL - 33

SP - 1

EP - 6

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 1

M1 - 4

ER -